Systemic Treatment of Non-Small Cell Lung Cancer

Edited by Giuseppe Giaccone

Oxford Oncology Library

Helpful Key Points at the beginning of each chapter to summarise content
Portable, accessible format for quick reference
Includes up-to-date research literature that has direct clinical application for busy healthcare professionals

Systemic Treatment of Non-Small Cell Lung Cancer

Edited by Giuseppe Giaccone

Description

Lung cancer is the leading cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Most patients present with advanced disease and five-year survival is low at about 15%. Surgery is the main treatment for early stage disease. If patients are deemed inoperable, systemic chemotherapy is considered. For patients with locally advanced disease, multimodality therapy is administered where chemotherapy is given in combination with definitive radiation therapy or surgery in selected cases. Cytotoxic chemotherapy regimens mainly consist of a platinum doublet. Biologic agents are increasingly being incorporated into treatment regimens.

This pocketbook summarises the latest evidence-based and practical information on the use of systemic therapies in the management of non-small cell lung cancer (NSCLC), for early stage, locally advanced, and metastatic disease. Including contributions from leading thoracic oncologists from North America and Europe, the book covers the range of therapies currently available to clinicians including cytotoxic chemotherapy, biologic therapies, and other novel agents. This book will serve as an invaluable reference for all health care professionals involved in the management of patients with NSCLC.

Systemic Treatment of Non-Small Cell Lung Cancer

Edited by Giuseppe Giaccone

Oxford Oncology Library

1. Molecular biology of lung cancer for the clinician, Adi F. Gazdar, Jill E. Larsen, and John D. Minna
2. Staging of lung cancer, Sofie De Craene, Kurt G Tournoy, and Jan P. van Meerbeeck
3. Systemic therapy of early stage NSCLC, Benjamin Besse and Jean Charles Soria
4. Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Margaret Edwards and Hak Choy
5. Systemic therapy of advanced NSCLC, efficacy, and toxicity, Taylor M. Ortiz and Pasi A. Janne
6. Systemic therapy for recurrent NSCLC, efficacy, and toxicity, Paul Wheatley-Price and Frances A. Shepherd
7. Palliative care in NSCLC, Paul Baas and Wilma Uyterlinde
8. Development of new therapeutic agents for treatment of NSCLC, Arun Rajan and Giuseppe Giaccone

Systemic Treatment of Non-Small Cell Lung Cancer

Edited by Giuseppe Giaccone

Oxford Oncology Library

Author Information

Giuseppe Giaccone, M.D., Ph.D. is an internationally recognized expert in the field of lung cancer and developmental therapeutics. Dr. Giaccone received his M.D. cum laude from the University of Torino Medical School in 1980, followed by training in clinical oncology and internal medicine, which he completed at the University of Torino in 1988. He spent the next two years in the NCI's Medical Oncology Branch. Following his training at the NCI, Dr. Giaccone received his Ph.D. from the Free University Medical Center in Amsterdam, The Netherlands. He then served as a senior medical oncologist at the Medical Center from 1990 to 2000, when he was appointed Professor of Medical Oncology. Dr. Giaccone became Head of the Center's Department of Medical Oncology in 2003. Dr. Giaccone has published more than 400 peer-reviewed papers and contributed to more than 30 book chapters. He has also played a major role in the European Organization for Research and Treatment of Cancer (EORTC).

Contributors:

Paul Baas, Netherlands Cancer Institute, Amsterdam, Netherlands
Benjamin Besse, Department of Medicine, Institut Gustave Roussy, Villejuif, France
Hak Choy, Radiation Oncology, Moncrief Building, Dallas, TX, USA
Sofie De Craene Department of Respiratory Medicine & Thoracic Oncology, University Hospital, Ghent, Belgium
Margaret Edwards, Radiation Oncology, Moncrief Building, Dallas, TX, USA
Adi F. Gazdar, Hamon Center for Therapeutic Oncology Research, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX ,USA
Giuseppe Giaccone, Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA, USA
Jill E. Larsen, Hamon Center for Therapeutic Oncology Research, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
John D. Minna, Hamon Center for Therapeutic Oncology Research, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
Taylor M. Ortiz, Dana-Farber Cancer Institute, Boston, MA, USA
Arun Rajan, Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
Frances A. Shepherd, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
Jean Charles Soria, Department of Medicine, Institut Gustave Roussy, Villejuif, France
Kurt G Tournoy, Department of Respiratory Medicine & Thoracic Oncology, University Hospital; Lung Oncological Network Ghent (LONG), Ghent, Belgium
Wilma Uyterlinde, Netherlands Cancer Institute, Amsterdam, Netherlands
Jan P. van Meerbeeck, Department of Respiratory Medicine & Thoracic Oncology, University Hospital; Lung Oncological Network Ghent (LONG), Ghent, Belgium
Paul Wheatley-Price, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada